• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Warning of an increased risk of vertebral fracture after stopping denosumab.停用地诺单抗后椎体骨折风险增加的警告。
CMAJ. 2018 Apr 23;190(16):E485-E486. doi: 10.1503/cmaj.180115.
2
Clinical vertebral fractures following denosumab discontinuation.狄诺塞麦停药后发生的临床椎体骨折。
Endocrine. 2016 Oct;54(1):271-272. doi: 10.1007/s12020-016-1030-6. Epub 2016 Jul 8.
3
Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis.地诺单抗治疗可降低绝经后骨质疏松症女性的二次骨折风险。
Climacteric. 2015;18(6):805-12. doi: 10.3109/13697137.2015.1045484. Epub 2015 Sep 28.
4
Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).绝经后日本骨质疏松症女性和男性接受三年地诺单抗治疗：地诺单抗骨折干预随机安慰剂对照试验（DIRECT）1年开放标签扩展研究的结果
Osteoporos Int. 2015 Feb;26(2):765-74. doi: 10.1007/s00198-014-2964-2. Epub 2014 Nov 18.
5
Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures.从地诺单抗转换为唑来膦酸对椎体骨折可能具有的保护作用。
Osteoporos Int. 2017 Oct;28(10):3067-3068. doi: 10.1007/s00198-017-4108-y. Epub 2017 Jun 6.
6
Vertebral fractures after denosumab cessation.地诺单抗停药后的椎体骨折
Cleve Clin J Med. 2020 Jun;87(6):337-338. doi: 10.3949/ccjm.87a.19152.
7
Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.地诺单抗停药后发生严重自发性椎体骨折：三例病例报告
Osteoporos Int. 2016 May;27(5):1923-5. doi: 10.1007/s00198-015-3380-y. Epub 2015 Oct 28.
8
Stopping Denosumab.停止地舒单抗治疗。
Curr Osteoporos Rep. 2019 Feb;17(1):8-15. doi: 10.1007/s11914-019-00502-4.
9
Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.地诺单抗停药后严重的反弹相关椎体骨折：9例临床病例报告
J Clin Endocrinol Metab. 2017 Feb 1;102(2):354-358. doi: 10.1210/jc.2016-3170.
10
Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment.停用地诺单抗治疗后，椎体骨折患者的破骨细胞生成增加。
Eur J Endocrinol. 2017 Jun;176(6):677-683. doi: 10.1530/EJE-16-1027. Epub 2017 Mar 10.

引用本文的文献

1
Real-world differences in denosumab persistence, reinitiation, and switching among cohorts of older adults in Canada and the United States.加拿大和美国老年人群体中地诺单抗持续使用、重新开始使用及换药情况的真实差异。
JBMR Plus. 2025 Apr 11;9(6):ziaf061. doi: 10.1093/jbmrpl/ziaf061. eCollection 2025 Jun.
2
Comparison of Hounsfield Units and Vertebral Bone Quality Score for the Prediction of Time to Pathologic Fracture in Mobile Spine Metastases Treated With Radiotherapy.比较Hounsfield单位和椎体骨质量评分对接受放疗的活动脊柱转移瘤病理性骨折发生时间的预测价值。
Global Spine J. 2025 Mar 4:21925682251325173. doi: 10.1177/21925682251325173.
3
Multiple Spontaneous Vertebral Fractures in a Younger Post-menopausal Woman Upon Stopping Denosumab Therapy.一名绝经后年轻女性停用地诺单抗治疗后出现多发性自发性椎体骨折
JCEM Case Rep. 2023 May 17;1(3):luad042. doi: 10.1210/jcemcr/luad042. eCollection 2023 May.
4
First Ecuadorian statement consensus for the evaluation and treatment of osteoporosis.厄瓜多尔首份骨质疏松评估和治疗共识声明。
Arch Osteoporos. 2023 Jun 15;18(1):81. doi: 10.1007/s11657-023-01263-5.
5
Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.40 岁及以上成年人在初级保健中进行脆性骨折一级预防的筛查：筛查和治疗效果及可接受性以及风险预测工具准确性的系统评价。
Syst Rev. 2023 Mar 21;12(1):51. doi: 10.1186/s13643-023-02181-w.
6
Real-World Safety and Effectiveness of Denosumab in Patients with Osteoporosis: A Prospective, Observational Study in South Korea.真实世界中地舒单抗治疗骨质疏松症患者的安全性和有效性：韩国的一项前瞻性观察性研究。
Endocrinol Metab (Seoul). 2022 Jun;37(3):497-505. doi: 10.3803/EnM.2022.1427. Epub 2022 Jun 3.
7
The current situation in the approach to osteoporosis in older adults in Turkey: areas in need of improvement with a model for other populations.土耳其老年人骨质疏松症治疗方法的现状：其他人群需要改进的领域和模式。
Arch Osteoporos. 2021 Nov 30;16(1):179. doi: 10.1007/s11657-021-01038-w.
8
Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020.2009 年至 2020 年骨质疏松症和恶性肿瘤相关骨病药物治疗的变化趋势。
J Gen Intern Med. 2022 Jun;37(8):1917-1924. doi: 10.1007/s11606-021-06938-8. Epub 2021 Jun 7.
9
Atypical femur fractures: current understanding and approach to management.非典型股骨骨折：当前的认识与处理方法
Ther Adv Musculoskelet Dis. 2020 Aug 21;12:1759720X20916983. doi: 10.1177/1759720X20916983. eCollection 2020.
10
Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction.根据年龄较大、合并症、虚弱和器官功能障碍对多发性骨髓瘤进行治疗的特殊考虑。
Crit Rev Oncol Hematol. 2019 May;137:18-26. doi: 10.1016/j.critrevonc.2019.02.011. Epub 2019 Feb 27.

本文引用的文献

1
An Essential Warning.
J Bone Miner Res. 2018 Feb;33(2):188-189. doi: 10.1002/jbmr.3359. Epub 2018 Jan 4.
2
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension.地舒单抗停药后发生的椎体骨折：一项 FREEDOM 随机安慰剂对照试验及其延伸的事后分析。
J Bone Miner Res. 2018 Feb;33(2):190-198. doi: 10.1002/jbmr.3337. Epub 2017 Nov 22.
3
Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.地舒单抗治疗骨质疏松症的停药：ECTS 的系统评价和立场声明。
Bone. 2017 Dec;105:11-17. doi: 10.1016/j.bone.2017.08.003. Epub 2017 Aug 5.
4
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.10 年地舒单抗治疗绝经后骨质疏松症妇女：来自 3 期随机 FREEDOM 试验和开放标签扩展的结果。
Lancet Diabetes Endocrinol. 2017 Jul;5(7):513-523. doi: 10.1016/S2213-8587(17)30138-9. Epub 2017 May 22.
5
Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases.停药后反跳相关椎体骨折 24 例患者的临床特征：系统评价及附加病例
J Bone Miner Res. 2017 Jun;32(6):1291-1296. doi: 10.1002/jbmr.3110. Epub 2017 Mar 13.
6
Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.美国患者在 2 年内停止使用注射性骨质疏松症治疗药物的频率。
Osteoporos Int. 2017 Apr;28(4):1355-1363. doi: 10.1007/s00198-016-3886-y. Epub 2017 Jan 5.
7
Uptake and characteristics of zoledronic acid and denosumab patients and physicians in Ontario, Canada: impact of drug formulary access.加拿大安大略省唑来膦酸和地诺单抗患者及医生的使用情况和特征：药物处方获取的影响
Osteoporos Int. 2015 May;26(5):1525-33. doi: 10.1007/s00198-014-3023-8. Epub 2015 Jan 21.
8
Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review.药物治疗预防骨折的效果比较：一项更新的系统评价。
Ann Intern Med. 2014 Nov 18;161(10):711-23. doi: 10.7326/M14-0317.
9
Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada.加拿大安大略省双膦酸盐的处方、持续使用和累积暴露情况。
Osteoporos Int. 2012 Mar;23(3):1075-82. doi: 10.1007/s00198-011-1645-7. Epub 2011 May 21.
10
Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.地舒单抗治疗及其停药对低骨量绝经后妇女骨密度和骨转换标志物的影响。
J Clin Endocrinol Metab. 2011 Apr;96(4):972-80. doi: 10.1210/jc.2010-1502. Epub 2011 Feb 2.

Warning of an increased risk of vertebral fracture after stopping denosumab.

作者信息

Symonds Christopher, Kline Gregory

机构信息

Division of Endocrinology and Metabolism, Department of Medicine, University of Calgary, Calgary, Alta.

出版信息

CMAJ. 2018 Apr 23;190(16):E485-E486. doi: 10.1503/cmaj.180115.

DOI:10.1503/cmaj.180115
PMID:29685907
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5915244/
Abstract
摘要